Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors

WALTHAM, Mass., Dec. 5, 2023. Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced it recently dosed its first patient in a Phase 1/1b study of the Company ' s proprietary IL-2...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials